Browse > Article
http://dx.doi.org/10.15616/BSL.2014.20.3.147

Comparison Analysis of Immune Cells between CT26 Tumor Bearing Mice and Normal Mice  

Lee, Na Kyung (Department of Biomedical Laboratory Science, Soon Chun Hyang University)
Kim, Hong Sung (Department of Biomedical Laboratory Science, Korea Nazarene University)
Abstract
It has well studied that immune cells are strongly related to tumor progression and tumor suppression. To identify the difference of immune cell between tumor bearing mice and normal mice, we examined systemically the immune cell of CT26 tumor bearing mice on 21 days after tumor cell administration. As previously reported, CD4+ and CD8+ T cells population of tumor bearing mice significantly decreased 38% and 30% on day 21 compared to that of normal mice, respectively. All subpopulation of CD4 and CD8+ T cell significantly decreased, except CD49b+ T cell subpopulation. But, myeloid cell population ($CD11b^{high}$ and all Gr-1+ subpopulation) of tumor bearing mice significantly increased on day 21. Especially, all subpopulation of CD11b+Gr-1+ cell of tumor bearing mice significantly increased on day 21. Also, Foxp3+$CD25^{high}$ CD4 T cell (regulatory T cells) population significantly increased on day 21. These results suggest that tumor can induce the decline of T lymphocyte and the expansion of myeloid cells and regulatory T cells, and provide the basic information for the study of tumor immunology.
Keywords
Tumor bearing mice; T cell; Regulatory T cells; Myeloid cell;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RR, Sica D, Tuason L, Klein E, Bukowski RM, Finke JH. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Research. 1993. 53: 1380-1387.
2 Balkwill F. Cancer and the chemokine network. Nature Reviews Cancer. 2004. 4: 540-550.   DOI   ScienceOn
3 Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation. 2005. 80: S254-264.   DOI   ScienceOn
4 Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002. 420: 860-867.   DOI   ScienceOn
5 Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunology. 2002. 3: 991-998.   DOI   ScienceOn
6 Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Reviews Immunology 2009. 9: 162-174.   DOI   ScienceOn
7 Heo CK, Bahk YY, Cho EW. Tumor-associated autoantibodies as diagnostic and prognostic biomarkers. BMB Reports. 2012. 45: 677-685.   DOI
8 Kandil A, Bazarbashi S, Mourad WA. The correlation of epsteinbarr virus expression and lymphocyte subsets with the clinical presentation of nodular sclerosing hodgkin disease. Cancer. 2001. 91: 1957-1963.   DOI
9 Kim HS, Kim-Schulze S, Kim DW, Kaufman HL. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1bb ligand. Cancer Research. 2009. 69: 8516-8525.   DOI
10 Klebanoff CA, Gattinoni L, Restifo NP. Cd8+ t-cell memory in tumor immunology and immunotherapy. Immunological Reviews. 2006. 211: 214-224.   DOI   ScienceOn
11 Kulbe H, Levinson NR, Balkwill F, Wilson JL. The chemokine network in cancer--much more than directing cell movement. The International Journal of Developmental Biology 2004. 48: 489-496.   DOI   ScienceOn
12 Moodycliffe AM, Maiti S, Ullrich SE. Splenic nk1.1-negative, tcr alpha beta intermediate cd4+ t cells exist in naive nk1.1 allelic positive and negative mice, with the capacity to rapidly secrete large amounts of il-4 and ifn-gamma upon primary tcr stimulation. Journal of Immunology. 1999. 162: 5156-5163.
13 Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A, De Baetselier P, Van Ginderachter JA. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct t cell-suppressive activity. Blood. 2008. 111: 4233-4244.   DOI   ScienceOn
14 Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nature Reviews Cancer. 2008. 8: 618-631.   DOI   ScienceOn
15 Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells. Advances in Experimental Medicine and Biology 2007. 601: 213-223.   DOI
16 Nomura T, Sakaguchi S. Naturally arising cd25+cd4+ regulatory T cells in tumor immunity. Current Topics in Microbiology and Immunology 2005. 293: 287-302.
17 Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer Journal. 2010. 16: 348-353.   DOI
18 Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of t cell tolerance induced by myeloid-derived suppressor cells. Journal of Immunology 2010. 184: 3106-3116.   DOI
19 Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H. Cd8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Research. 1998. 58: 3491-3494.
20 Pellicci DG, Hammond KJ, Coquet J, Kyparissoudis K, Brooks AG, Kedzierska K, Keating R, Turner S, Berzins S, Smyth MJ, Godfrey DI. Dx5/cd49b-positive t cells are not synonymous with cd1d-dependent nkt cells. Journal of Immunology 2005. 175: 4416-4425.   DOI
21 Sakaguchi S. Naturally arising foxp3-expressing cd25+cd4+ regulatory t cells in immunological tolerance to self and non-self. Nature Immunology 2005. 6: 345-352.   DOI   ScienceOn
22 Sakaguchi S, Sakaguchi N. Regulatory t cells in immunologic self-tolerance and autoimmune disease. International Reviews of Immunology 2005. 24: 211-226.   DOI
23 Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory t lymphocytes with distinct homing potentials and effector functions. Nature. 1999. 401: 708-712.   DOI   ScienceOn
24 Terabe M, Berzofsky JA. The role of nkt cells in tumor immunity. Advances in Cancer Research. 2008. 101: 277-348.   DOI
25 Whiteside TL. Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Seminars in Cancer Biology. 2006. 16: 3-15.   DOI
26 Willimsky G, Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing t-cell tolerance. Nature. 2005. 437: 141-146.   DOI   ScienceOn
27 Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Lienard D, Lejeune F, Rimoldi D, Guillaume P, Meidenbauer N, Mackensen A, Rufer N, Lubenow N, Speiser D, Cerottini JC, Romero P, Pittet MJ. Effector function of human tumorspecific cd8 t cells in melanoma lesions: A state of local functional tolerance. Cancer Research. 2004. 64: 2865-2873.   DOI
28 Youn JI, Collazo M, Shalova IN, Biswas SK, Gabrilovich DI. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. Journal of Leukocyte Biology 2012. 91: 167-181.   DOI
29 Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity. European Journal of Immunology 2010. 40: 2969-2975.   DOI
30 Yu P, Lee Y, Liu W, Krausz T, Chong A, Schreiber H, Fu YX. Intratumor depletion of cd4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. The Journal of Experimental Medicine 2005. 201: 779-791.   DOI   ScienceOn